Anti-Cancer Compound Looks Promising

 “You have cancer.”
For the 14 million people who are diagnosed every year with this disease, there are few words more frightening. However, there may be new hope.
According to Propanc Health Group (OTCBB: PPCH), results from a recent study for its lead product, PRP, confirm that its anti-cancer compound has the potential to fight a wide range of cancer types, such as kidney, brain, prostate, liver and lung cancers.
The findings are important because up until recently the trend with cancer treatment has been towards ever-costlier drugs aimed at ever-narrower niches on the cancer spectrum, according to an article in The UK Times last month. But recent advancements in immunotherapy and cancer genome sequencing have opened up the possibility that fewer drugs can be used to help the body fight numerous types of cancers.
PRP is a naturally derived proenzyme formulation that seeks to halt cancer progression and spreading by eradicating cancer stem cells while leaving normal stem cells unaffected.
“I have no doubt PRP represents a new therapeutic drug class with significant potential,” said Dr. Julian Kenyon, Propane’s chief scientific officer.
Dr. Kenyon said there is reason to be cautiously optimistic since his previous experience using a proenzyme treatment in the clinic on terminally ill patients suffering from a broad range of cancers helped them survive longer than anticipated, free from any severe, or serious side effects.
Propanc said it will submit a clinical trial application in the UK later this year, initially targeting patients with advanced solid tumors in Phase I, followed by pancreatic and ovarian cancers in Phase II trials. The trials will allow Propanc to qualify for orphan drug designation, which the company intends to prepare and apply for after its meeting with the Medicines and Healthcare products and Regulatory Agency (MHRA).
“Together with the enhancement of our intellectual property and plans to seek orphan drug designation, we’re at the right time to initiate discussions with potential licensing partners looking to add a new therapeutic drug class to their portfolio,” said James Nathanielsz, Propanc’s chief executive officer.
Nathanielsz added that currently the company is sufficiently capitalized to fund the early stage development of PRP.
According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers is expected to reach more than $12 billion by 2020.
For More Info, Contact Us.

How to Prevent Dehydration

Its essential to drink water with specific amount daily. Usually in sunny weather loss of water occurs in our bodies, so it good to drink water with regular interval to maintain transpiration level.
It’s in every living cell, tissue and organ, and it’s second only to oxygen as the thing we need most to survive—pure, clean water. We can’t live without it, and we can’t live well without enough of it. We are constantly in need of water as we lose water with every breath and every activity of the body. We are especially at risk for dehydration when we exercise or we are ill—this is when dehydration, even mild dehydration, can take its toll, causing you to feel tired and drained of energy. Anyone may become dehydrated, but young children, older adults and people with chronic illnesses are most at risk.

Doctors Look for Handsome Package

As consumers are asked to assume more health care costs than in the past, it’s important to consider benefits packages that offer more holistic support besides the usual health, dental and vision policies. Consumers should know that there are plans available today that will promote their overall well-being, which includes physical, mental and financial health.

Luckily, many employers see the need for robust benefits offerings, with some incorporating new solutions to meet increased employee demand for more from their benefits provider. In fact, 34 percent of employers surveyed in a Towers Watson study indicated they already offer more customization with voluntary benefits. Companies like Aflac are expanding services, ranging from credit monitoring to supplemental accident benefits to helping provide employees and their families with financial protection.

As consumers select benefits options provided by their employer, here are three additional services to look for that go above and beyond a typical benefits offering:

    • Fraud protection. According to the Identity Theft Resource Center, by the middle of 2015, there were a total of 424 data breaches, compromising millions of consumers’ personal and financial data. It’s no surprise that the use of mobile technology and digital transactions has left consumers vulnerable, so benefits that include services to help protect employees’ personal and financial information should be viewed as a must-have option in employer-sponsored packages.

    • Telemedicine. A Towers Watson survey showed that almost half of employers offer telemedicine, and by 2018 that number is expected to rise to 90 percent. Companies are starting to connect consumers to highly qualified health care professionals who can evaluate common conditions and provide personalized treatment remotely, offering a low-cost and convenient option, as opposed to a hospital or urgent care visit.

    • Benefits management support. According to the Consumer Financial Protection Bureau, medical debts account for 52 percent of debt collection actions that appear on consumer credit reports. Not to mention, the Kaiser Family Foundation found that 1 in 3 Americans struggle to pay medical bills. Companies are beginning to offer administrative support to help negotiate employees’ unpaid medical bills. Consumers who are concerned about expenses should investigate these options further, as it could help them protect their financial future.

Chiropractors May Surprise You

You know how comforting it is to see a degree framed on the wall when you visit some professional’s office?
Well, next time you consult a doctor of chiropractic, get ready to feel very, very comforted.
That’s because his or her degree attests to the rigorous training — a minimum of seven years of higher education, including clinical patient management — that doctors of chiropractic must complete. Not everyone, though, apparently realizes what that means in terms of better health outcomes for patients.
“Doctors of chiropractic are not only trained in problems dealing with the spine, but are formally educated in clinical examination and diagnosis — with a focus on conservative health care interventions for the well-being of the whole person,” explains Sherry McAllister, DC, executive vice president of the not-for-profit Foundation for Chiropractic Progress.
Among the required coursework:
* Basic sciences of anatomy, physiology, neurology, biomechanics, microbiology and pathology.
* Ethics and integrity.
* Clinical sciences, including nutrition, rehabilitation and therapeutic procedures.
* Research methodology.
The importance of quality education for chiropractors was recognized as early as 1935, when the National Chiropractic Association created a Committee on Educational Standards. That ultimately led to the formation of the Council on Chiropractic Education, which is recognized by the U.S. Department of Education as the accrediting agency for schools’ educational and clinical programs leading to the award of a doctor of chiropractic degree.

Muscle Loss Can Be Slowed

It’s natural to lose both muscle mass and bone density. In fact, according to research, muscle loss starts as early as 30 years old.
The good news is that it doesn’t have to be that way.
To understand how to prevent muscle loss over time, you have to understand the science behind muscle growth.
One key regulator of muscle growth is a protein called myostatin. Myostatin exerts an effect on both muscle hypertrophy and hyperplasia, increasing both the number of muscle fibers and fiber sizes. Hypertrophy refers to the increase in the size of muscle cells. In contrast, hyperplasia refers to an increase in the number of cells.
In layman’s terms, myostatin regulates how large muscles can get.
It follows that by inhibiting this naturally occurring protein, it would be easier to build muscle.
“So when you get rid of the myostatin gene entirely, you see more muscle fibers, and then you get bigger muscle fibers,” Se-Jin Lee, a professor at Johns Hopkins, told NPR in an interview.
One bionutritional supplement that is getting a lot of attention is MYOS Corporation’s Fortetropin, a myostatin inhibitor that has been clinically shown to demonstrate positive effects on both muscle thickness and lean body mass. Fortetropin is the active ingredient in MYOS’ Re Muscle Health nutritional products. The “Re” in “Re Muscle Health” stands for Rebuild, Rejuvenate, Results.
“The data from the study conducted in our human performance laboratory clearly demonstrates that Fortetropin resulted in significant muscle gains in recreationally trained individuals,” said Jacob Wilson, an assistant professor at the University of Tampa, where the study was conducted.
MYOS Chief Medical Officer Robert Ashton said the daily use of Fortetropin combined with exercise “could be beneficial in improving lean muscle mass, which has significant therapeutic effects for overall health, including regulating insulin and glucose levels and combating osteoporosis.”
Adding nutritional supplements, like those found at Re Muscle Health, may help slow the effects of muscle loss. The products, which can be used daily to supplement a sensible workout routine, include bars, powders and meal-replacement shakes, and are formulated to help protect and preserve lean, healthy muscle tissue. The products contain a full day’s serving of Fortetropin, and 20 grams of protein.
For more information, Contact Us.

Cancer Center May Help You Quit Tobacco

A cancer center is taking a unique approach to getting cigarette smokers to quit by suggesting they use smokeless tobacco as an alternative.
The James Graham Brown Cancer Center and the University of Louisville have aimed their “Switch and Quit” campaign –headed by Brad Rodu, professor of medicine at the University of Louisville — at Owensboro, Ky., a city that has the nation’s highest smoking rates (it kills about 220 residents a year), in a state that leads the nation in tobacco growth and export.
It is an understatement to say this program — which was started in 2011 and continues today — has an uphill battle in getting Owensboro residents to switch, but as Dr. Donald Miller, an oncologist and director of the cancer center told USA Today in an interview, “this is as reasonable a scientific hypothesis as anybody has come up with and it needs to be tried.”
Supporters of the program say that smokers who switch to smokeless tobacco rather than nicotine patches or gum, are more likely to give up cigarettes. For the 46 million Americans who smoke, that could be welcome news.
“If nicotine can be delivered in a less harmful way, millions of lives could be saved in the United States,” Radu said.
Bolstering Radu’s research is a 2007 report from the Royal College of Physicians in London, which suggested that some smokeless tobacco products are about 90 percent less harmful than cigarettes.
This is also good news for tobacco accessory producers like FLASR, an Atlanta-based company that has created portable spittoons.
“If more people turn to smokeless tobacco, they’re going to need an easy and discreet way to enjoy their product of choice without attracting attention,” says FLASR CEO Everett Dickson.
To that end, FLASR has created a flask that has an advanced closing mechanism, ensuring that it stays securely closed when not being used, which eliminates the risk of embarrassing spills and leaks so often seen with cups and bottles. In addition, the 4-ounce pocket-sized spittoon is designed to allow users to open and shut it with just one hand, making it an ideal solution, no matter where you go.
“Finding a way to let people have their nicotine that carries less risk, it’s the realistic solution,” said one oncologist.
For more information, Contact Us.

New Drug for the Treatment of Cancer Patients

Biotech is the new buzzword for 2015, and these companies are making a big splash these days, offering potential investors a compelling array of options. Among those to watch is Propanc Health Group Corporation (PPCH). Propanc is a developmental-stage health care company that is currently focusing its efforts in the field of new treatments for chronic diseases, particularly solid tumor cancers. The company was established in 2007 and is headquartered in Melbourne, Australia.
Propanc recently announced early data from animal studies using its patented formulas. Propanc’s in-development proteolytic proenzyme products (described by the company as inactive precursors of enzymes) were not associated with any adverse effects in the early studies, and the company is prepared to take the next steps in research. According to the company’s website, Propanc “intends to undertake Phase I, II, and III clinical trials to assess the safety and efficacy of our product in specific patient populations.”
Propanc’s proenzyme products, known as PRP and PRP-DCM, have the potential to be game-changers in the field of cancer care by offering effective options for long-term therapy without the excessive toxicity associated with many current cancer treatments. The company says the research is preliminary, and the findings need to be confirmed in clinical trials. However, the company’s stated development goals focus on the targeting of solid tumors, conditions for which most currently available treatments are limited to stabilizing the tumors or extending patients’ lives for only a few months. Solid tumor cancers include lung, colorectal, ovarian, pancreatic and liver, to name a few.
As the company states, “In each of these indications, there is a large market opportunity to capitalize on the limitations of current therapies.”
Scientists don’t yet fully understand how proenzyme products can fight cancer, but early research results suggest that they may contribute to an inhibition of growth factors that cause cancer. Additionally, Propanc is exploring a method to shrink tumor masses by targeting the tumor directly with an injectable form of PRP.
Propanc also is working with research collaborators to explore how its proenzyme products impact cancer cells. The goal of this research is to provide an opportunity for new, patentable drug development by the company.
For more details, Contact us.